Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Arq. bras. neurocir ; 40(2): 137-145, 15/06/2021.
Artigo em Inglês | LILACS | ID: biblio-1362201

RESUMO

Background Today, there is a need for new and independent additional advanced markers that can predict the prognosis of meningioma patients, postoperatively. The present study aimed to find out postoperative short-term prognostic markers in patients with meningioma using their demographic data and routine blood biochemistry findings evaluated preoperatively. Methods The Glasgow Coma Scale (GCS), and Glasgow Outcome Scale (GOS) scores of the patients were recorded. Additionally, preoperatively obtained serum glucose, Creactive protein (CRP), sodium, potassium, creatinine, blood urea nitrogen, aspartate aminotransferase (AST), alanine aminotransferase, and hemoglobin level values, platelet, leukocyte, neutrophil, lymphocyte, eosinophil, basophil, andmonocyte count results, erythrocyte sedimentation rate (ESR), neutrophil-lymphocyte ratio, plateletlymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR) values were evaluated. Results In the present study, 23 operated patients with meningioma World Health Organization (WHO) grade 1 (17 females, 6 males) were included. Correlation test results revealed that the GCS score, platelet count, and serum potassium level values could directly predict the short-term prognosis of these patients. Additionally, these test results suggested that the lymphocyte, monocyte, and eosinophil count values, PLR, LMR, ESR, serum glucose, CRP, and AST level values could be indirect markers in predicting the short-term prognosis. However, likelihood ratio test results revealed that only monocyte count value, LMR value, and serum CRP level value could be the markers for prediction of the short-term prognosis. Conclusion At the end of the present study, it was concluded that the monocyte count value, LMR value, and serum CRP level value could be the best markers in predicting the short-term prognosis of the operated meningioma patients.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Análise Química do Sangue/métodos , Biomarcadores , Meningioma/terapia , Contagem de Plaquetas , Potássio/sangue , Prognóstico , Proteína C-Reativa/química , Monócitos/química , Estudos Retrospectivos , Interpretação Estatística de Dados , Estatísticas não Paramétricas , Correlação de Dados
2.
Acta cir. bras ; 33(2): 125-133, Feb. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-886259

RESUMO

Abstract Purpose: To investigate the biochemical, histopathologic, and spermatogenetic changes in the detorsionated testicle after experimental torsion and to study the antioxidant effects of pheniramine maleate and nebivolol. Methods: Twenty-four Sprague-Dawley male rats were divided into 4 groups: Group 1: Sham; Group 2: Torsion/Detorsion (T/D); Group 3: T/D + Pheniramine maleate (PM); Group 4: T/D + Nebivolol (NB) group. Paroxanase (PON), total antioxidant status (TAS), total oxidant status (TOS), and oxidative stres index (OSI) were measured, and spermatogenetic and histopathologic evaluation was performed in tissue and blood samples. Results: The evaluation of tissue TAS indicated no statistically significant difference in Group 3 compared to Group 2. A statistically significant increase was detected in Group 4 compared to Group 2. Serum PON levels revealed a statistically significant increase in Groups 3 and 4 compared to Groups 1 and 2. The Johnsen testicular biopsy score decreased in Groups 3 and 4, but the decrease was not statistically significant. Conclusions: Pheniramine maleate and nebivolol have antioxidant effects against ischemia-reperfusion damage. They also support tissue recovery, which is more significantly observed by nebivolol.


Assuntos
Animais , Masculino , Ratos , Feniramina/farmacologia , Torção do Cordão Espermático/tratamento farmacológico , Testículo/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Nebivolol/farmacologia , Antioxidantes/farmacologia , Torção do Cordão Espermático/patologia , Espermatogênese/efeitos dos fármacos , Testículo/irrigação sanguínea , Testículo/patologia , Fatores de Tempo , Traumatismo por Reperfusão/tratamento farmacológico , Ratos Sprague-Dawley , Antagonistas Adrenérgicos beta/farmacologia , Arildialquilfosfatase/sangue , Antagonistas dos Receptores Histamínicos H1/farmacologia
3.
Acta cir. bras ; 30(6): 414-421, 06/2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-749644

RESUMO

PURPOSE: To investigate the protective effect of dexmedetomidine (Dex) on testicular damage induced by ischemia-reperfusion injury in rats. METHODS: Sham group underwent left scrotal exploration only (group 1). The ischemia-reperfusion only group underwent left testicular torsion and detorsion (group 2). The ischemia-reperfusion plus Dex group underwent left testicular torsion, received 50 µg/kg Dex (group 3) and 100 µg/kg Dex (group 4) intraperitoneally at minute 180 of ischemia and then underwent detorsion. We determined histopathological findings and performed specific biochemical analyses. RESULTS: Increasing doses of Dex significantly increased TAS, and significantly decreased OSI. Analyzing the antioxidant effects of increasing doses of Dex in torsion and contrlateral testicles: Dex 100 µg/kg statistically significant increased the tissue total antioxidant status (TAS) and oxidative stress index (OSI) when compared with Dex 50 µg/kg but not found significantly change on the tissue total oxidant status (TOS). However, Dex did not significantly improve these histological alterations. CONCLUSION: The antioxidant effects of dexmedetomidine on testicular ischemia-reperfusion injury in ipsilateral and contrlateral testis, but in the histopathological level, there was no difference statistically according to Johnsen's scoring system between groups at both sides. .


Assuntos
Animais , Masculino , /farmacologia , Antioxidantes/farmacologia , Dexmedetomidina/farmacologia , Traumatismo por Reperfusão/prevenção & controle , Torção do Cordão Espermático/prevenção & controle , Testículo/irrigação sanguínea , /uso terapêutico , Dexmedetomidina/uso terapêutico , Imuno-Histoquímica , Isquemia/patologia , Isquemia/prevenção & controle , Estresse Oxidativo/efeitos dos fármacos , Estudos Prospectivos , Distribuição Aleatória , Ratos Wistar , Valores de Referência , Traumatismo por Reperfusão/patologia , Índice de Gravidade de Doença , Torção do Cordão Espermático/patologia , Fatores de Tempo , Testículo/patologia
4.
Indian J Biochem Biophys ; 2013 Jun; 50(3): 215-220
Artigo em Inglês | IMSEAR | ID: sea-147305

RESUMO

The aim of the present study was to investigate serum homocysteine levels in patients with erectile dysfunction and to evaluate the relationship between serum homocysteine levels and response to the standard 50 mg phosphodiesterase 5 inhibitor treatment. Twenty-eight erectile dysfunction patients having normal vascular parameter according to Penile Doppler Ultrasonography and twenty healthy subjects were enrolled in the study. All subjects filled The International Index of Erectile Function (IIEF) questionnaire. A total of 4-6 doses of phosphodiesterase 5 inhibitor (sildenafil 50 mg) were given to patients. Later, they were divided into two groups as sildenafil responder and non-responder. Serum homocysteine levels were compared in groups based on sildenafil response. Compared with healthy subject, higher homocysteine levels were observed in patients with erectile dysfunction (p = 0.005), especially in sildenafil non-responder group (p = 0.005). There was significant negative correlation between homocysteine and IIEF scores in group responder to sildenafil treatment (r = -0.698, p = 0.008). Mean IIEF scores of patients with non-responder to sildenafil 50 mg were lower than those of controls (p = 0.0001), but mean IIEF scores of patients with responders approached values observed in control subjects (p = 0.002). The results indicated that measurement of serum homocysteine levels could be used as a marker for the evaluation of efficacy of phosphodiesterase 5 inhibitor and the selection of efficacious alternative therapies.


Assuntos
Adulto , Biomarcadores/sangue , Disfunção Erétil/sangue , Disfunção Erétil/tratamento farmacológico , Homocisteína/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde/métodos , Inibidores da Fosfodiesterase 5/administração & dosagem , Piperazinas/administração & dosagem , Purinas/administração & dosagem , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Sulfonas/administração & dosagem , Resultado do Tratamento , Vasodilatadores/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA